PT  - JOURNAL ARTICLE
AU  - Nicolas Marincek
AU  - Piotr Radojewski
AU  - Rebecca A. Dumont
AU  - Philippe Brunner
AU  - Jan Müller-Brand
AU  - Helmut R. Maecke
AU  - Matthias Briel
AU  - Martin A. Walter
TI  - Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial
AID  - 10.2967/jnumed.114.147256
DP  - 2015 Feb 01
TA  - Journal of Nuclear Medicine
PG  - 171--176
VI  - 56
IP  - 2
4099  - http://jnm.snmjournals.org/content/56/2/171.short
4100  - http://jnm.snmjournals.org/content/56/2/171.full
SO  - J Nucl Med2015 Feb 01; 56
AB  - Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients. Methods: Patients with progressive unresectable meningioma were treated with 90Y-DOTATOC and 177Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival. Results: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001–0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004–0.63; n = 34; P = 0.019) were associated with longer survival. Conclusion: 90Y-DOTATOC and 177Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.